Advance Your Solid Tumor Research with Tailored Support

Worldwide’s personalized support can help drive your oncology program forward.

We are here to help — contact us today to discuss your study needs

Recent advancements in biomarker discovery are transforming cancer research, making it essential to integrate scientific, medical, and operational considerations. This white paper offers insights into key factors for early phase trials, best practices for biomarker sample collection, and the impact of biomarker selection on commercialization.

Download the white paper to gain valuable insights and advance your oncology research and development

Full-Service Oncology Operations

Solid tumor research continues to advance rapidly with novel technologies that require nuanced expertise. Our team has helped conduct more than 85 solid tumor studies, spanning study design consultations, study transitions, full clinical trials in immuno-oncology, novel monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Our expertise extends beyond solid tumors to include liquid tumors, diverse treatment modalities, rare oncology, and other complex programs.

Solid Tumor Trial Complexity: A Puzzle We Love Solving

Solid tumor trials face unique challenges, including tumor heterogeneity, the need to identify biomarkers, complex trial design, and ensuring full regulatory compliance across different agencies. We have experience beyond traditional 3×3 study designs, working into novel approaches including mTPI, BOIN, BLRM, and backfill BOIN — our experts enjoy establishing innovative solutions.

Your Trial’s Success Is a Shared Passion

At Worldwide, we understand the life-changing role of novel solid tumor treatments for those who need them. Those impacted by solid tumor cancer need people they can trust, and we work tirelessly with the patient base and advocacy groups to help improve the prognostic narrative for everyone affected, including caregivers and family. We give you and your trial full attention every step of the way, including an open-door policy with our senior leadership.